XML 1033 R77.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 9 Months Ended 194 Months Ended
Sep. 30, 2012
Sep. 30, 2012
Cash flows from operating activities:    
Net loss $ (8,422) $ (261,971)
Adjustments to reconcile net loss to net cash used in operating activities:    
Accretion of interest on notes payable, net of amortization of debt premium   100
Amortization of investment premiums, net   (2,297)
Change in valuation of Economic Rights (27) (27)
Change in valuation of other liabilities measured at fair value (51) (6,378)
Depreciation 45 12,600
Amortization of intangible assets   886
Fixed asset impairment   221
Unrealized foreign exchange loss   7,747
Deferred revenue   (98)
Compensation for warrants issued to non-employees   1,215
Shares issued for IP rights   446
(Gain) loss on disposal of property, plant and equipment (62) 38
Goodwill and intangibles impairment   7,934
Stock based compensation 287 19,310
Provision for restructuring   1,779
Amortization of issuance costs of Preferred Ordinary "C" shares   2,517
Transaction costs on sale of Economic Rights 33 33
Gain on termination of distribution agreement (1,192) (1,192)
Changes in operating assets and liabilities:    
Prepaid expenses, inventory and other current assets 25 (33)
Accounts payable, accrued liabilities and other current liabilities (220) (5,533)
Net cash used in operating activities (9,584) (222,703)
Investing activities:    
Purchase of ALIGN   (3,763)
Purchase of property, plant and equipment (12) (8,849)
Proceeds from sale of property, plant and equipment 62 225
Purchase of short-term investments   (156,657)
Redemptions of short-term investments, net of maturities   162,729
Net cash provided by (used in) investing activities 50 (6,315)
Financing activities:    
Payment of capital lease obligations   (3,719)
Proceeds from issuance of ordinary and preferred ordinary shares, net of issuance costs   121,678
Proceeds from issuance of common stock, warrants and economic rights, net of issuance costs 2,886 94,557
Proceeds from the exercise of stock options and warrants, net of issuance costs 48 221
Payment of preferred stock dividend   (1,898)
Repayment of government loan   (455)
Government loan received   414
Loan received from Cyclacel Group Plc   9,103
Proceeds of committable loan notes issued from shareholders   8,883
Loans received from shareholders   1,645
Cash and cash equivalents assumed on stock purchase   17,915
Costs associated with stock purchase   (1,951)
Net cash provided by financing activities 2,934 246,393
Effect of exchange rate changes on cash and cash equivalents (12) 462
Net (decrease) increase in cash and cash equivalents (6,612) 17,837
Cash and cash equivalents, beginning of period 24,449  
Cash and cash equivalents, end of period 17,837 17,837
Cash received during the period for:    
Interest 10 11,756
Taxes 556 18,763
Cash paid during the period for:    
Interest   (1,914)
Schedule of non-cash transactions:    
Acquisitions of equipment purchased through capital leases   3,470
Issuance of common shares in connection with license agreements   592
Issuance of ordinary shares on conversion of bridging loan   1,638
Issuance of preferred ordinary "C" shares on conversion of secured convertible loan notes and accrued interest   8,893
Issuance of ordinary shares in lieu of cash bonus   164
Issuance of other long term payable on ALIGN acquisition   $ 1,122